Vasopressin, also called antidiuretic hormone, is produced by the hypothalamus and released from the posterior pituitary gland. In its classical physiological role, it binds V2 receptors in the kidney to promote water reabsorption and acts on V1 receptors in vascular smooth muscle to regulate blood pressure. Over the past two decades, however, researchers have documented that vasopressin receptors are also found on a range of tissues where they have no obvious role in fluid homeostasis, including certain tumors. In breast cancer in particular, the aberrant presence of vasopressin and its receptors has attracted interest as both a potential biomarker and a potential point of therapeutic attack, a framing that the new study takes up directly.

Triple-negative breast cancer, which lacks the estrogen receptor, progesterone receptor, and HER2 amplification that define other breast cancer subtypes, remains one of the most difficult malignancies to treat because it responds poorly to hormonal therapies and targeted agents that have transformed outcomes for other patient groups. While patients with hormone receptor-positive disease can often be managed for years with endocrine therapies, and HER2-positive disease is now treated effectively with antibodies and kinase inhibitors against that target, triple-negative tumors offer few such molecular handles. Treatment has therefore relied largely on chemotherapy, and although immunotherapy has recently expanded the options for some patients, the outlook for many with triple-negative disease remains worse than for other subtypes. This unmet need drives continued interest in identifying new vulnerabilities in these tumors.

The MDA-MB-231 cell line used in this study is a standard laboratory model of invasive, triple-negative disease, widely used because it recapitulates key features of aggressive tumors, including their motility, invasiveness, and resistance to many conventional agents. The researchers chose it in part because these cells express the V1A subtype of the vasopressin receptor, a G protein-coupled receptor that sits in the cell membrane and initiates multiple downstream signaling cascades when activated by the hormone. Like many G protein-coupled receptors, the V1A receptor does not simply remain at the cell surface: after ligand binding, it is drawn into the cell interior through clathrin-mediated endocytosis, a process by which the plasma membrane folds inward, pinches off, and delivers the receptor-ligand complex into intracellular vesicles. This internalization is not merely housekeeping; it shapes the duration, intensity, and location of the signaling that follows receptor activation.

The experimental design centered on a simple but clinically relevant question: if vasopressin binding to its receptor drives both mitogenic signaling and the internalization of that receptor through clathrin-mediated endocytosis, could blocking the endocytic machinery alter the hormone's effects on cancer cell survival? Dynamin 2, a large GTPase enzyme, is an integral component of the membrane scission step during receptor endocytosis, and dynasore is a well-characterized, cell-permeable small molecule that halts its GTPase activity. The team exposed the cells to 100 nanomolar vasopressin for 24 hours, either alone or in combination with dynasore, and compared the results against untreated controls and against cells treated with wortmannin, a selective inhibitor of phosphoinositide 3-kinase that shuts down the PI3K/AKT survival pathway.

The PI3K/AKT axis is one of the most heavily studied survival circuits in cancer biology. When growth factor receptors are active, PI3K generates lipid second messengers at the inner face of the membrane, which recruit AKT to the membrane where it is activated and then promotes cell survival, growth, and proliferation through a cascade of downstream effectors including mTOR. Hyperactivation of this pathway is common across many cancers and is associated with resistance to chemotherapy and other treatments. Wortmannin, by blocking the catalytic activity of PI3K, prevents the production of these lipid messengers and thereby starves the survival pathway of its triggering input.

The researchers assessed a battery of cellular outcomes, including cytotoxicity, apoptosis, autophagy-mediated cell death, cell cycle progression, cell migration and invasion, and the expression of genes associated with drug resistance. Apoptosis was measured alongside the expression of key regulators of programmed cell death, while autophagy was tracked through the microtubule-associated protein LC3II and Beclin1 messenger RNA levels, both of which are standard markers of autophagic flux. Cell cycle distribution was analyzed to determine whether the treatments arrested cells at a particular checkpoint, and migration assays were used to probe the invasive behavior that makes triple-negative breast cancer particularly dangerous in patients.

The results revealed a clear pattern of cooperation between vasopressin and the endocytic inhibitor. Vasopressin alone induced apoptosis in approximately 20 percent of the cells, a modest but measurable effect. When dynasore was added to the culture alongside the hormone, the apoptotic fraction rose to 28 percent, indicating that blocking Dynamin 2 potentiated the cell-killing effect of vasopressin signaling. This increase in cell death was accompanied at the molecular level by overexpression of Bax, a pro-apoptotic member of the Bcl-2 family, and Caspase-3, the executioner enzyme that carries out the final dismantling of the cell during apoptosis. Together, these findings suggest that the combination pushed cells more decisively down the intrinsic apoptotic pathway than either agent could achieve on its own.

Parallel experiments with wortmannin, which targets the PI3K/AKT axis rather than the endocytic machinery, produced comparable results. Wortmannin alone induced apoptosis in 29 percent of cells, and when combined with dynasore, that figure rose to 35 percent, the highest apoptotic fraction observed in the study. The fact that dynasore enhanced the cytotoxicity of both vasopressin and wortmannin suggests that Dynamin 2 inhibition may act as a general sensitizer of triple-negative breast cancer cells to agents that disrupt survival signaling, rather than as a partner specific to one particular drug or pathway.

Autophagy, the cellular recycling process that can either protect cells from stress or contribute to their demise depending on context, behaved differently depending on the treatment. In cells exposed to vasopressin, either alone or with dynasore, the autophagy markers LC3II and Beclin1 mRNA increased, indicating that the hormone pushed cells toward autophagy-associated cell death. In contrast, cells treated with wortmannin, alone or with dynasore, showed decreased levels of these markers, suggesting that PI3K inhibition suppresses rather than stimulates autophagic activity in this cellular context. This divergence highlights that vasopressin and wortmannin, despite both ultimately killing the cells, appear to engage partially distinct death programs. The distinction matters for translational work, because autophagy can either facilitate or frustrate cell death depending on the drug combination, and knowing which death program a treatment engages can inform rational pairing with other agents.

Beyond cell death, the combination treatments produced effects on other hallmarks of cancer aggressiveness. Cells receiving the dual treatments of vasopressin plus dynasore, or wortmannin plus dynasore, showed decreased activation of AKT, the central kinase of the PI3K survival pathway, and downregulation of the multidrug resistance gene MDR1, which encodes a membrane pump responsible for expelling chemotherapeutic drugs from cells and is a major contributor to treatment failure in many cancers. Reducing MDR1 expression could, in principle, restore sensitivity to standard chemotherapy agents that these pumps would otherwise export. The treated cells also accumulated in the G0/G1 phase of the cell cycle, indicating that the combinations halted progression through the cell cycle before DNA replication could begin. Migration and invasion, the cellular behaviors that underlie metastatic spread, were regressed by the treatments as well, a notable finding given that metastasis is the principal cause of death in triple-negative breast cancer patients.

The mechanistic picture that emerges from these findings is one in which vasopressin binding to the V1A receptor normally triggers both clathrin-mediated endocytosis of the hormone-receptor complex and downstream intracellular signaling through diacylglycerol and cyclic AMP-dependent pathways. When dynasore halts the GTPase activity of Dynamin 2 and disrupts its PIP2-mediated oligomerization, receptor internalization is impaired, and the endocytic block itself appears to contribute cytotoxic stress. In parallel, wortmannin selectively inhibits the conversion of PIP2 to PIP3 by PI3K, thereby shutting down the PI3K/AKT/mTOR survival pathway. The convergence of these two modes of disruption on AKT inactivation and MDR1 downregulation provides a plausible explanation for why the combinations outperformed single-agent treatments.

The study builds on earlier work by the same group, published in 2022, which examined the effects of vasopressin and dynamin 2 or PI3K/AKT inhibition in luminal A breast cancer cells. In that earlier model, vasopressin induced apoptosis but did not enhance the antiproliferative effect of dynamin 2 or PI3K/AKT inhibition, a contrast that suggests the hormone's therapeutic potential may depend on the molecular subtype of the tumor. The V1A receptor expression in the triple-negative cells used in the current study may be a key variable, and the authors' findings raise the possibility that vasopressin receptor status could serve as a biomarker for selecting patients who might benefit from combination strategies involving endocytic or PI3K pathway inhibition.

Several important limitations temper the clinical significance of these results. The experiments were conducted entirely in a single cell line over a 24-hour treatment window, and the concentrations used, while pharmacologically relevant in vitro, do not address questions of drug delivery, toxicity to normal tissues, or pharmacokinetics in a living organism. Vasopressin itself has potent cardiovascular effects through its role in regulating blood pressure and fluid balance, and any therapeutic application would likely require analogues engineered to minimize these systemic actions, an approach already explored with desmopressin derivatives in preclinical breast cancer models. Dynasore, while a valuable research tool, is known to have dynamin-independent effects on cellular membranes, and the authors note that some of the cytotoxic events observed may arise from such off-target actions rather than from Dynamin 2 inhibition alone. Validation in additional cell lines, in animal models, and with more clinically suitable inhibitors would be necessary before these findings could inform treatment strategies.

Nevertheless, the study contributes a mechanistically grounded rationale for exploring combinations that pair vasopressin receptor signaling with disruption of endocytic trafficking or PI3K survival signaling in triple-negative breast cancer.

The therapeutic paradigm shift explored in this trial capitalizes on the transformative potential of radiotherapy to convert PDAC tumors from immunologically “cold”—meaning unresponsive to immune attacks—to “hot,” thereby sensitizing them to immunotherapy. The immunogenic conversion fundamentally enhances the tumor’s susceptibility to immune checkpoint inhibitors, specifically anti-programmed cell death protein 1 (PD-1) targeted therapy. This strategic synergy aims to amplify the immune system’s ability to recognize and eradicate tumor cells, which traditionally evade detection in this cancer subtype.

Ivonescimab represents a new frontier in immunotherapy as a bispecific antibody adept at simultaneously targeting PD-1 and vascular endothelial growth factor (VEGF). By inhibiting VEGF, Ivonescimab not only disrupts tumor angiogenesis—a vital process for tumor growth and metastasis—but also modifications the pancreatic cancer microenvironment. VEGF blockade remodels this typically immunosuppressive environment into one that permits immune effector cells to infiltrate and attack the malignancy more effectively when combined with PD-1 inhibition.

The clinical trial, registered under NCT06844422, is designed as a single-arm, Phase Ib/II study, involving 37 patients diagnosed with LAPC. The Phase Ib segment primarily focuses on establishing the maximum tolerated dose (MTD) and identifying any dose-limiting toxicities (DLTs) of Ivonescimab. Employing a classical 3+3 dose-escalation design over four weeks, researchers meticulously titrate the dosage to define a recommended Phase II dose (RP2D), ensuring maximum efficacy blended with manageable safety profiles.

Transitioning into Phase II, the trial’s endpoint sharpens its focus on progression-free survival (PFS), a critical metric indicative of therapeutic benefit in this context. Patients receive the RP2D of Ivonescimab in conjunction with precise SBRT administration—a regimen delivering radiation doses ranging between 25 to 50 Gy over five fractions within two weeks—followed by tailored cycles of modified FOLFIRINOX chemotherapy. This chemotherapy combination, consisting of oxaliplatin, irinotecan, leucovorin, and fluorouracil, remains a cornerstone therapy for pancreatic cancer and is leveraged here to maximize cytotoxic effects synergistically with Ivonescimab and radiation.

A notable aspect of the study design is its emphasis on maintenance therapy. Patients who tolerate the combination regimen can continue with Ivonescimab monotherapy for up to 12 months or until disease progression or intolerable toxicity arises. This approach aims to sustain immune pressure on the tumor, potentially prolonging remission and delaying resistance.

The rationale underlying this multifaceted treatment strategy resides in recent translational research revealing that PDAC’s notoriously hostile tumor microenvironment attenuates the efficacy of single-modality immunotherapies. By strategically combining SBRT, chemotherapy, and dual blockade of PD-1 and VEGF pathways, the trial hopes to surmount the barriers posed by the dense stromal environment and immunosuppressive signals prevalent in PDAC.

Previous preclinical and clinical studies have hinted at the potential of anti-VEGF therapies to normalize tumor vasculature, decrease hypoxia, and reduce regulatory T-cell populations, collectively fostering a milieu more amenable to immune attack. Similarly, the use of stereotactic body radiotherapy offers localized high-dose radiation capable of releasing tumor antigens and upregulating immunogenic markers, further enhancing systemic anti-tumor immune responses.

Safety remains a paramount concern in this vulnerable patient population, and the Phase Ib segment’s structured dose-escalation ensures rigorous monitoring of adverse events. Dose-limiting toxicities, if observed, will inform dose adjustments to balance maximal therapeutic efficacy with patient safety—a critical consideration given the combinatorial therapy’s intensity.

The implications of this trial extend beyond individual patient outcomes. Should the therapy demonstrate a significant extension in progression-free survival or overall survival, it could reshape first-line treatment protocols for LAPC, a disease for which curative options remain circumscribed. Moreover, the study’s findings can catalyze further research into bispecific antibody therapies that simultaneously target multiple axes of tumor progression and immune evasion.

This trial also underscores the mounting significance of precision oncology, wherein treatments are no longer one-size-fits-all but intricately tailored based on the tumor’s immunobiological characteristics and microenvironmental context. The integration of advanced imaging, cytological analyses, and molecular profiling before enrollment exemplifies the meticulous patient selection aimed at optimizing therapeutic responsiveness.

The investigators anticipate that success in combining Ivonescimab with guided SBRT and chemotherapy could establish a new standard of care, mitigating the high morbidity associated with pancreatic cancer. Furthermore, the exploration of immune checkpoint and VEGF co-inhibition may open therapeutic avenues for other solid tumors marked by similar immunosuppressive microenvironments.

As the trial progresses, its rigorous methodology and innovative approach will contribute invaluable insights into the treatment resistance mechanisms intrinsic to pancreatic cancer. This knowledge will not only assist oncologists in clinical decision-making but may also drive the development of next-generation immunotherapeutic agents.

Early data dissemination from this study could also invigorate the oncology community’s efforts toward combinatorial immunotherapy regimens, highlighting how traditional treatments, like radiotherapy and chemotherapy, can synergistically complement immunomodulatory drugs. Such multidisciplinary approaches reflect the evolving complexity and sophistication in cancer management strategies.

In conclusion, this trial represents a bold and innovative stride against a formidable adversary in pancreatic cancer. By harnessing Ivonescimab’s dual-targeting capabilities alongside precise radiotherapy and chemotherapy, researchers aspire to tip the balance in favor of durable remission and improved quality of life for patients facing this daunting diagnosis. The oncology field awaits the results eagerly, which promise to be a pivotal chapter in the ongoing battle against PDAC.

Subject of Research: The study investigates the efficacy and safety of Ivonescimab, a bispecific antibody targeting PD-1 and VEGF, combined with stereotactic body radiotherapy (SBRT) and chemotherapy in patients with locally advanced pancreatic cancer (LAPC).

Article Title: Study protocol for a single-arm phase Ib/II trial of Ivonescimab combined with adapted guided stereotactic body radiotherapy and chemotherapy in patients with locally advanced pancreatic cancer.

Article References:
Tang, Z., Shi, F., Zhu, K. et al. Study protocol for a single-arm phase Ib/II trial of Ivonescimab combined with adapted guided stereotactic body radiotherapy and chemotherapy in patients with locally advanced pancreatic cancer. BMC Cancer 25, 1581 (2025). https://doi.org/10.1186/s12885-025-14944-w

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14944-w